N1-(1-cyanocyclopropyl)-S-isobutyl-N2-((1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)-L-cysteinamide | 1259967-42-4

• 英文名称: N1-(1-cyanocyclopropyl)-S-isobutyl-N2-((1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)-L-cysteinamide
• 英文别名: (2R)-N-(1-cyanocyclopropyl)-3-(2-methylpropylsulfanyl)-2-[[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino]propanamide
• CAS: 1259967-42-4
• 化学式: C₁₉H₂₃F₄N₃OS
• 分子量: 417.471
• InChiKey: IVKPWFYXYBPYKF-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  90.2
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES
  申请人：Black Cameron

  公开号：US20120101053A1

  公开（公告）日：2012-04-26

  The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds of the invention include, but are not limited to, mammalian parasitic diseases in which the parasite utilizes a critical cysteine protease from the papain family. Examples of parasitic diseases to be treated or prevented by the compounds of the invention include, but are not limited to, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, coccidiosis, giardiosis, cryptosporidiosis or schistosomiasis.

  本发明涉及一种能够抑制和/或减少一种或多种蛋白酶（包括但不限于cathepsins和木瓜样半胱氨酸蛋白酶）活性的化合物，从而治疗和/或预防与一种或多种半胱氨酸蛋白酶相关的各种疾病状态。本发明的化合物治疗和/或预防的疾病状态包括但不限于寄生虫病，其中寄生虫利用来自木瓜家族的关键半胱氨酸蛋白酶。本发明的化合物可用于治疗或预防的寄生虫疾病的例子包括但不限于弓形虫病、疟疾、非洲锥虫病、恙虫病、利什曼病、球虫病、贾第鞭毛虫病、隐孢子虫病或血吸虫病。